PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression

References

• Moretta L, Pietra G, Vacca P, Pende D, Moretta F, Bertaina A, Mingari MC, Locatelli F, Moretta A. Human NK cells: from surface receptors to clinical applications. Immunol Lett. 2016;178:15–19. doi:10.1016/j.imlet.2016.05.007.
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity: the example of natural killer cells. Science. 2011;331:44–349. doi:10.1126/science.1198687.
   PubMed Web of Science ®Google Scholar
• Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. Immunity. 2017;47(5):820–833. doi:10.1016/j.immuni.2017.10.008.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. Blood. 2001;97(10):3146–3351. doi:10.1182/blood.V97.10.3146.
   PubMed Web of Science ®Google Scholar
• Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolisis. Annu Rev Immunol. 2001;19:197–223. doi:10.1146/annurev.immunol.19.1.197.
   PubMed Web of Science ®Google Scholar
• Morisaki T, Onishi H, Katano M. Cancer immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res. 2012;32(6):2241–2247.
   PubMed Web of Science ®Google Scholar
• Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. Receptors for HLA class-I molecule in human natural killer cells. Annu Rev Immunol. 1996;14:619–648. doi:10.1146/annurev.immunol.14.1.619.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242. doi:10.1111/j.1600-065X.2010.00923.x.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001;22(5):265–268. doi:10.1016/S1471-4906(01)01888-9.
   PubMed Web of Science ®Google Scholar
• Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543–9953. doi:10.1128/MCB.25.21.9543-9553.2005.
   PubMed Web of Science ®Google Scholar
• Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883–895. doi:10.1084/jem.20051776.
   PubMed Web of Science ®Google Scholar
• Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci. 2015;36(9):587–595. doi:10.1016/j.tips.2015.06.005.
   PubMed Web of Science ®Google Scholar
• Dondero A, Pastorino F, Della Chiesa M, Corrias MV, Morandi F, Pistoia V, Olive D, Bellora F, Locatelli F, Castellano A, et al. PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology. 2016;5(1):e1064578. doi:10.1080/2162402X.2015.1064578.
   PubMed Web of Science ®Google Scholar
• Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Moretta A, Marcenaro E. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139(1):335–346e3. doi:10.1016/j.jaci.2016.04.025.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, Peng J, Gao L, Liang X, Ma C. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36(44):6143–6153. doi:10.1038/onc.2017.209.
   PubMed Web of Science ®Google Scholar
• Beldi-Ferchiou A, Lambert M, Dogniaux S, Vely F, Vivier E, Olive D, Dupuy S, Levasseur F, Zucman D, Lebbe C, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget. 2016;7(45):72961–72977. doi:10.18632/oncotarget.12150.
   PubMedGoogle Scholar
• Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24(1):26. doi:10.1186/s12929-017-0329-9.
   PubMedGoogle Scholar
• He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep. 2015;5:13110. doi:10.1038/srep13110.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44(6):1255–1269. doi:10.1016/j.immuni.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol. 2005;235(2):109–116. doi:10.1016/j.cellimm.2005.07.007.
   PubMed Web of Science ®Google Scholar
• Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy – advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016;7. doi:10.3389/fimmu.2016.00091.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–824. doi:10.1093/intimm/dxm057.
   PubMed Web of Science ®Google Scholar
• Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. 2017;8(57):97671–97682. doi:10.18632/oncotarget.18311.
   PubMedGoogle Scholar
• Pentcheva-Hoang T, Chen L, Pardoll DM, Allison JP. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A. 2007;104(45):17765–17770. doi:10.1073/pnas.0708767104.
   PubMed Web of Science ®Google Scholar
• Elhag OA, Hu XJ, Wen-Ying Z, Li X, Yuan YZ, Deng LF, Liu DL, Liu YL, Hui G. Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity. Asian Pac J Cancer Prev. 2012;13(8):4031–4036.
   PubMedGoogle Scholar
• Kruger S, Legenstein ML, Rosgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, et al. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology. 2017;6(5):e1310358. doi:10.1080/2162402X.2017.1310358.
   PubMed Web of Science ®Google Scholar
• Sorensen SF, Demuth C, Weber B, Sorensen BS, Meldgaard P. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. Lung Cancer. 2016;100:77–84. doi:10.1016/j.lungcan.2016.08.001.
   PubMed Web of Science ®Google Scholar
• Thaventhiran T, Alhumeed N, Yeang HX, Sethu S, Downey JS, Alghanem AF, Olayanju A, Smith EL, Cross MJ, Webb SD, et al. Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist. mAbs. 2014;6(5):1290–1299. doi:10.4161/mabs.29758.
   PubMed Web of Science ®Google Scholar
• Goltz D, Gevensleben H, Dietrich J, Ellinger J, Landsberg J, Kristiansen G, Dietrich D. Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncoimmunology. 2016;5(10):e1221555. doi:10.1080/2162402X.2016.1221555.
   PubMed Web of Science ®Google Scholar
• Rover LK, Gevensleben H, Dietrich J, Bootz F, Landsberg J, Goltz D, Dietrich D. PD-1 (PDCD1) Promoter methylation is a prognostic factor in patients with diffuse lower-grade gliomas harboring isocitrate dehydrogenase (IDH) mutations. EBioMedicine. 2018;2:97–104. doi:10.1016/j.ebiom.2018.01.016.
   Google Scholar